New hope for advanced cancer patients: experimental drug BL-ARC002 enters human trials
NCT ID NCT07591155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called BL-ARC002 in 22 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the drug by injection and be closely monitored for side effects and any signs of cancer control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a new imaging tracer outperform standard scans in finding hidden tumors?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Lab-Made immune protein takes on advanced cancers in first human test